MX369111B - Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. - Google Patents

Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.

Info

Publication number
MX369111B
MX369111B MX2016013048A MX2016013048A MX369111B MX 369111 B MX369111 B MX 369111B MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 369111 B MX369111 B MX 369111B
Authority
MX
Mexico
Prior art keywords
treatment
inhibitor
combination
nras
mutated cancer
Prior art date
Application number
MX2016013048A
Other languages
English (en)
Other versions
MX2016013048A (es
Inventor
Anthony Edward Cross Darren
Anne Eberlein Catherine
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016013048A publication Critical patent/MX2016013048A/es
Publication of MX369111B publication Critical patent/MX369111B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a los métodos para identificar resistencia a la terapia para cáncer, mediante la identificación de una mutación E63K NRAS, una mutación G12V NRAS o una ganancia del número de copias del gen NRAS. Un aspecto adicional de la invención se refiere a métodos de tratamiento que pueden superar tales mecanismos de resistencia, que implican el uso de un inhibidor de EGFR en combinación con un inhibidor de MEK para el tratamiento de cánceres que implican una mutación NRAS seleccionada de E63K, G12V, G12R, G12A, G12D, G12S y G12C, y/o cáncer que implica una ganancia del número de copias del gen NRAS.
MX2016013048A 2014-04-04 2015-04-02 Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. MX369111B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975088P 2014-04-04 2014-04-04
US201462013573P 2014-06-18 2014-06-18
PCT/GB2015/051042 WO2015150826A1 (en) 2014-04-04 2015-04-02 Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer

Publications (2)

Publication Number Publication Date
MX2016013048A MX2016013048A (es) 2017-04-27
MX369111B true MX369111B (es) 2019-10-29

Family

ID=52824498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013048A MX369111B (es) 2014-04-04 2015-04-02 Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.

Country Status (15)

Country Link
US (2) US20200237758A1 (es)
EP (1) EP3125885B1 (es)
JP (1) JP6549147B2 (es)
KR (1) KR102406334B1 (es)
CN (1) CN106456774A (es)
AU (1) AU2015242407B2 (es)
CA (1) CA2943402C (es)
DK (1) DK3125885T3 (es)
ES (1) ES2890556T3 (es)
HU (1) HUE055747T2 (es)
MA (1) MA39841A (es)
MX (1) MX369111B (es)
PL (1) PL3125885T3 (es)
RU (1) RU2683276C2 (es)
WO (1) WO2015150826A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110038A1 (es) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086467A1 (en) * 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
BRPI0921888A2 (pt) * 2008-11-11 2015-12-29 Lilly Co Eli terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
RS60190B1 (sr) * 2011-07-27 2020-06-30 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za lečenje raka
KR102080535B1 (ko) * 2011-11-23 2020-02-24 메디뮨 엘엘씨 Her3에 특이적인 결합 분자 및 이의 용도
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
EP2884971A4 (en) * 2012-08-16 2016-01-06 Ohio State Innovation Foundation STAT3 INHIBITORS AND THEIR ANTICANCER USE
US20140066465A1 (en) * 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
EP3125885A1 (en) 2017-02-08
WO2015150826A1 (en) 2015-10-08
DK3125885T3 (da) 2021-09-27
US20210177844A1 (en) 2021-06-17
KR20160135362A (ko) 2016-11-25
RU2016140626A (ru) 2018-05-07
ES2890556T3 (es) 2022-01-20
CN106456774A (zh) 2017-02-22
RU2683276C2 (ru) 2019-03-27
AU2015242407A1 (en) 2016-10-13
CA2943402A1 (en) 2015-10-08
HUE055747T2 (hu) 2021-12-28
MA39841A (fr) 2017-02-08
AU2015242407B2 (en) 2017-11-09
EP3125885B1 (en) 2021-06-30
JP2017511341A (ja) 2017-04-20
MX2016013048A (es) 2017-04-27
US20200237758A1 (en) 2020-07-30
CA2943402C (en) 2022-12-13
PL3125885T3 (pl) 2021-12-06
JP6549147B2 (ja) 2019-07-24
RU2016140626A3 (es) 2018-10-23
KR102406334B1 (ko) 2022-06-07

Similar Documents

Publication Publication Date Title
MX2021006234A (es) Perfilado molecular de proxima generacion.
EP3287774B8 (en) Data processing device for x-ray examination, and computer implemented data processing method
MX359781B (es) Método y dispositivo para ocultar información de privacidad.
MX2018002741A (es) Metodo y aparato para determinar datos volumetricos de una caracteristica anatomica predeterminada.
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2019013634A (es) Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
GB2553556B (en) Data processing apparatuses, methods, computer programs and computer-readable media
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX369111B (es) Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.
EP3555309C0 (en) EPIGENETIC MARKERS AND ASSOCIATED METHODS AND MEANS OF DETECTION AND MANAGEMENT OF OVARIAN CANCER
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
PT3282373T (pt) Validação e integração de dados de folha de cálculo de colaboração
MX2019000775A (es) Linea de montaje con inspeccion visual elctronica integrada.
IL267315A (en) Methods of determining colorectal cancer status in an individual
EP3271483A4 (en) Methods and materials for assessing and treating cancer
GB201615266D0 (en) Data processing apparatuses, methods, computer programs and computer-readable media
NZ752443A (en) Lasofoxifene treatment of er+ breast cancer
EP3521818A4 (en) COLORECTAL CANCER DIAGNOSIS DEVICE AND METHOD FOR PROVIDING COLORECTAL CANCER DIAGNOSIS INFORMATION
GB2599566B (en) Data processing apparatuses, methods, computer programs and computer-readable media
MX2019001214A (es) Metodos para el diagnostico de neoplasia de origen ginecologico.
EP3672619A4 (en) MATERIALS AND METHODS FOR EVALUATING CANCER RISK AND TREATING CANCER

Legal Events

Date Code Title Description
FG Grant or registration